BioSpace News Archive

A clinical study funded by Atos Medical, a leading company in laryngectomy care, reveals clinical trial results that demonstrate a significant reduction in coughing, shortness of breath, and skin irritation in the patient group adhering to daily care routines with their Heat and Moisture Exchangers (HMEs).

CareDx, Inc. announced the availability of XenoSure™ donor-derived cell-free DNA and XenoMap™ gene-expression profiling for investigational use in xenotransplantation research and post-xenotransplant clinical monitoring.

LogicMark , Inc. (NASDAQ: LGMK) announced today that its fourth quarter and full year 2021 financial and operating results will be released before the market opens on March 30, 2022 .

Huma Therapeutics Limited today announced a new partnership with AstraZeneca to scale innovation for digital health.

Silence Therapeutics plc and Mallinckrodt plc today announced filing of a clinical trial application (CTA) for SLN501, an siRNA targeting the complement C3 protein, triggering a $3 million milestone payment to Silence.

9 Meters Biopharma, Inc. today provided an overview of its recent achievements, important upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2021.

Mednow Inc. (“Mednow’’ or the “Company”) (TSXV:MNOW), Canada’s on-demand virtual pharmacy, is pleased to announce it has released its financial results for the period ending January 31st, 2022 (“Q2 2022”).

VectivBio Holding AG today announced new preclinical data supporting the potential of apraglutide, a next-generation, long-acting GLP-2 analog, as a novel treatment of steroid-refractory GI aGVHD following allogeneic hemopoietic stem cell transplant (HSCT).

Elysium Health, Inc.™, a leading life sciences company focused on aging research, has entered into a material transfer agreement with the University of Oxford to examine hundreds of samples from the VITACOG study to develop epigenetic measures of brain aging and health.

Eikon Therapeutics, Inc. today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022.